Multiple myeloma (MM) stands as the second most common hematologic malignancy. Proteasome inhibitors are effective in MM, but many patients develop resistance, which is thought to be caused by mutations in the PSMB5 gene.
Onkure Inc. has described phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and scoliosis (CLOVES syndrome), and PIK3CA-related overgrowth spectrum (PROS).
Sironax Ltd. has divulged nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) activators reported to be useful for the treatment of cancer, neurodegeneration, inflammation, and mitochondrial, metabolic, cardiovascular, muscle and renal disorders, among others.
Ildong Pharmaceutical Co. Ltd. has identified novel tetraheterocycle compounds acting as GTPase KRAS inhibitors reported to be useful for the treatment of cancer.
Erasmus University Rotterdam has disclosed compounds targeting fibroblast activation protein-α (FAPα) reported to be useful for the diagnosis and treatment of cancer.
Researchers from Abbvie Inc. recently presented preclinical data for ABBV-706, an SEZ6-targeted topoisomerase 1 (TOP1) inhibitor antibody-drug conjugate (ADC), being developed for the treatment of small-cell lung cancer (SCLC) and other SEZ6-expressing cancers.
Proviva Therapeutics Ltd. scientists hypothesized that both the activation of IL-2 receptor (IL-2R) and the blockade of programmed cell death protein 1 (PD-1) are complementary and potentially synergistic as a combination therapy for treating cancer.
RSS
